Pricing Log in Create free account
Saturday 17 October 2026 Export DVA’s income statement to Excel — free account

DaVita Inc.

DVA Healthcare Medical Care Facilities

DaVita Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.6 billion, up 6.46% from fiscal 2024. In the quarter to June 2026, revenue grew 5.17%, EPS grew 56.5%, free cash flow grew 49.4% and total debt rose 4.40%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years.

187.31 1.85 −0.98%
Market cap
$12.1B
P/E
15.0×
Fwd P/E
13.1×
Dividend yield
—
F-score
6/9
Altman Z
1.49
Beneish M
−2.59
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Insider Decisions trades per month

Total sells 454.33
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — 1 — — — 5 2 1 — — —
Insider Ownership 3.55%

Capital & Financial Ratios $m

Market Cap 12,070.00
Revenue 14,009.65
Net Income 1,189.54
Free Cash Flow 1,625.97
Net Debt 10,045.76
Current Ratio 1.47
Debt/Equity (22.44) (negative: negative equity)
P/E ratio 15.01
Fwd P/E 13.10
P/S ratio 0.87
P/B ratio 0.00
Past 5Y EPS Growth 9.29%
This Y EPS Growth 37.53% (at or above 15%: strong)
Next Y EPS Growth 14.41%
Next Y revenue growth 3.77%
Next 5Y EPS Growth 21.92% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.6×, against a ten-year median of 1.7×; over the ten years it ranged from 1.3× in 2023 to 2.8× in 2017.
P/E against its own 10 years 44.82%
10-year low 10-year high
P/S against its own 10 years 36.38%
10-year low 10-year high
EV/Sales against its own 10 years 38.78%
10-year low 10-year high
EV/FCF against its own 10 years 30.15%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2028 Powerpack
2027 Powerpack
2026 Powerpack
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 476 931 782 772
Receivables 2,416 2,558 2,959 3,117
Inventory 143 135 161 152
Other — — — —
3,138 3,746 4,058 4,190
2023 2024 2025 Q'26
Payables 515 547 696 716
ST’ Debt 123 271 309 154
Other 829 934 893 827
2,642 2,973 3,142 2,855

Compound Annual Growth %

10y 5y 3y
Sales 3.17% 3.39% 5.53%
Cash Flow 1.94% (0.95%) 6.44%
Earnings 10.72% (0.70%) 10.04%
Book Value 0.00% 0.00% 0.00%

Revenue $m

Mar Jun Sep Dec Year
’26 3,416 3,554 — — —
’25 3,224 3,380 3,420 3,620 13,643
’24 3,071 3,187 3,264 3,295 12,816
’23 2,873 3,000 3,121 3,146 12,140
’22 2,818 2,927 2,949 2,917 11,610
’21 2,820 2,917 2,938 2,944 11,619
’20 2,841 2,880 2,924 2,905 11,551
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 321 490 — — —
’25 180 324 842 541 1,887
’24 (135) 799 810 548 2,022
’23 463 450 661 485 2,059
’22 322 188 711 344 1,565
’21 154 680 567 530 1,931
’20 360 651 483 485 1,979
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 223 321 — — —
’25 47 215 685 397 1,345
’24 (249) 680 677 385 1,518
’23 328 333 503 357 1,552
’22 210 149 452 150 1,079
’21 26 544 426 294 1,351
’20 237 553 337 227 1,355
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 2.87 4.02 — — —
’25 2.00 2.58 2.04 3.29 9.84
’24 2.65 2.50 2.50 3.09 10.73
’23 1.25 1.91 2.62 1.62 7.42
’22 1.61 2.30 1.13 0.74 5.85
’21 2.09 2.64 2.36 1.79 8.90
’20 1.89 1.62 1.28 1.50 6.31
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 54.50 52.51 48.25 43.40 62.20 94.38 65.28 71.51 103.40 112.54

Analyst estimates 2026–2028

Powerpack
High 78.77 72.93 80.71 75.30 117.65 136.48 124.81 116.97 169.52 179.60
People
People Employees 70,300 74,500 77,700 65,000 67,000 69,000 70,000 70,000 76,000 78,000
Revenue/emp, $m 0.15 0.15 0.15 0.18 0.17 0.17 0.17 0.17 0.17 0.17
Income, $m
Income, $m Revenue 10,707 10,877 11,405 11,388 11,551 11,619 11,610 12,140 12,816 13,643
Gross margin, % 30.59 29.76 28.14 30.50 30.84 31.38 29.29 31.47 32.91 32.25
EBT 1,623 1,400 1,048 1,195 1,318 1,518 966 1,177 1,530 1,347
EBT margin, % 15.16 12.87 9.19 10.50 11.41 13.07 8.32 9.70 11.94 9.87
Net income 1,033 831 333 1,021 995 1,212 782 957 1,251 1,079
Depreciation 720 777 591 615 630 681 733 745 724 715
Per share, $
Per share, $ Revenue 53.10 57.66 66.78 74.35 96.42 110.41 124.85 133.72 150.79 183.80
Earnings 4.36 3.52 0.93 5.29 6.46 9.30 6.03 7.62 11.02 10.06
Cash flow 9.78 10.14 10.37 13.53 16.52 18.35 16.82 22.68 23.79 25.42
Capex (3.79) (4.31) (4.90) 20.31 (5.21) (5.51) (5.22) (5.58) (5.93) (7.30)
Free cash flow 5.99 5.83 5.47 33.84 11.31 12.84 11.60 17.10 17.86 18.12
Book value 24.05 25.90 22.88 15.14 13.08 8.90 9.42 13.70 4.66 (5.03)
Shares, m 202 189 171 153 120 105 93 91 85 74
Valuation, ×
Valuation, × P/E 14.96 20.67 61.26 13.95 18.23 12.26 12.52 14.05 13.56 11.23
P/S 1.23 1.26 0.77 1.01 1.22 1.03 0.60 0.80 0.99 0.62
P/B 2.71 2.80 2.25 4.96 8.98 12.79 7.95 7.80 32.11 0.00
EV/Sales 1.98 2.07 1.62 1.61 1.87 1.75 1.33 1.45 1.66 1.33
EV/FCF 17.61 20.44 19.79 3.55 15.98 15.05 13.58 10.18 12.74 11.94
Cash, $m
Cash, $m Operating cash flow 1,972 1,913 1,772 2,072 1,979 1,931 1,565 2,059 2,022 1,887
Capex (764) (813) (837) 3,111 (624) (580) (486) (507) (504) (542)
Free cash flow 1,208 1,100 935 5,183 1,355 1,351 1,079 1,552 1,518 1,345
Balance, $m
Balance, $m Working capital 1,284 5,703 3,533 1,318 673 769 536 496 773 916
Total debt 9,105 9,336 10,102 8,108 8,086 8,908 8,924 8,392 9,447 10,473
Net debt 8,123 8,784 9,684 6,888 7,564 8,331 8,507 7,915 8,516 9,691
Shareholders’ equity 4,850 4,886 3,908 2,319 1,567 936 876 1,244 396 (374)
Returns, %
Returns, % ROA 4.72 3.52 0.84 4.45 4.51 5.74 3.29 4.09 5.48 4.30
ROIC 9.78 8.29 7.02 11.16 11.60 12.12 8.92 10.94 14.66 13.71
ROE 17.71 13.63 3.62 26.04 39.82 78.19 61.85 65.24 114.19 6,746.19
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

DaVita Inc. vs peers in Medical Care Facilities (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
THC Tenet Healthcare Corporation $22.2B 10.3× 6.4× +14.61% (above 0%: growing) +212.97% (above 0%: growing) −43.88% (below 0%: shrinking) 46.78% 24.85% Compare
EHC Encompass Health Corporation $12.6B 20.6× 16.8× +9.58% (above 0%: growing) +9.93% (above 0%: growing) −45.01% (below 0%: shrinking) 100.00% 17.85% Compare
DVA DaVita Inc. $12.1B 15.0× 13.1× +5.17% (above 0%: growing) +56.49% (above 0%: growing) +49.36% (above 0%: growing) 32.70% 16.29%
FMS Fresenius Medical Care AG & Co. KGaA $11.8B 11.5× 12.5× +3.89% (above 0%: growing) +6.82% (above 0%: growing) +1.57% (above 0%: growing) 26.95% 9.58% Compare
UHS Universal Health Services, Inc. $11.0B 7.5× 6.1× +8.27% (above 0%: growing) +9.47% (above 0%: growing) −23.78% (below 0%: shrinking) 90.87% 11.14% Compare
ENSG The Ensign Group, Inc. $10.4B 26.9× 24.1× +17.33% (above 0%: growing) +16.22% (above 0%: growing) +12.24% (above 0%: growing) 16.65% 8.50% Compare
PACS PACS Group, Inc. $7.6B 27.6× 16.8× +9.07% (above 0%: growing) +45.45% (above 0%: growing) +220.51% (above 0%: growing) 17.07% 7.66% Compare
CHE Chemed Corporation $6.7B 25.7× 20.4× +8.80% (above 0%: growing) +42.78% (above 0%: growing) −43.51% (below 0%: shrinking) 32.90% 13.25% Compare
CON Concentra Group Holdings Parent, Inc. $5.0B 24.9× 17.0× +10.03% (above 0%: growing) +45.71% (above 0%: growing) +91.62% (above 0%: growing) 31.70% 18.99% Compare
Median of peers $10.7B 22.7× 16.8× +9.33% +29.50% −11.11% 32.30% 12.20%

All 55 Medical Care Facilities stocks →

DVA metrics, ten years each

DaVita Inc. (DVA) key facts

  • Concern: Net income was $1.1 billion, or $10.06 per share (basic), a net margin of 5.47%.
  • Strength: DaVita Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.6 billion, up 6.46% from fiscal 2024.
  • DaVita Inc. (DVA) is a Medical Care Facilities company in the Healthcare sector, listed on the New York Stock Exchange.
  • As of October 16, 2026, DVA traded at $187.31, a market capitalization of $12.1 billion.
  • At that price the stock trades at 15.0× trailing-twelve-month earnings and 0.9× sales; its P/E is higher than 45% of its own readings over the past ten years.
  • Return on equity was 6,746.2% and debt-to-equity -22.44.
  • Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 1.49 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

DaVita Inc. (DVA) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/DVA · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com